Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
It is the first autotaxin inhibitor to be investigated in cancer patients
ANVISA issues CGMP to Concord Biotech’s Unit I
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Subscribe To Our Newsletter & Stay Updated
